Bradley P. Dixon, MD

Professor of Pediatrics and Medicine
University of Colorado School of Medicine
Aurora, Colorado, United States

Presentation(s):

• Pegcetacoplan for Adolescents With Complement 3 Glomerulopathy or Primary Immune Complex-Membranoproliferative Glomerulonephritis: VALIANT Phase 3 Placebo-Controlled Trial Subgroup Analysis

  Friday, April 25, 2025
  4:00pm – 4:15pm HST

  Disclosure(s): Alexion, Astra Zeneca Rare Disease (Ongoing) (Products/Services: Consultant); Apellis Pharmaceuticals (Ongoing) (Products/Services: Consultant, Research Support including clinical trials & the principal or named investigator); Arrowhead Pharmaceuticals (Terminated, January 1, 2023) (Products/Services: Consultant); Calliditas Therapeutics (Terminated, August 28, 2024) (Products/Services: Consultant); Novartis Pharmaceuticals (Ongoing) (Products/Services: Consultant, Research Support including clinical trials & the principal or named investigator); Roche Genentech Pharmaceuticals (Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator)